Various exemplary surgical adjuncts with medicants affected by activator materials are provided. In general, an adjunct is provided with at least one medicant that is configured to be activated by an activator material. The adjunct can be delivered to a tissue of a patient, where the adjunct can be implanted. Various activator materials can be configured to activate the at least one medicant retained by the adjunct, the activation causing any one or more of a variety of actions. For example, the at least one medicant can be activated so as to yield at least one of a signal and/or an effect on the adjunct.

Various exemplary surgical adjuncts with medicants affected by activator materials are provided. In general, an adjunct is provided with at least one medicant that is configured to be activated by an activator material. The adjunct can be delivered to a tissue of a patient, where the adjunct can be implanted. Various activator materials can be configured to activate the at least one medicant retained by the adjunct, the activation causing any one or more of a variety of actions. For example, the at least one medicant can be activated so as to yield at least one of a signal and/or an effect on the adjunct.

Described herein are polymers and associated methods to occlude structures and malformations of the vasculature with polymers with delayed controlled rates of expansion. Methods of forming such devices are also disclosed.

Described herein are polymers and associated methods to occlude structures and malformations of the vasculature with polymers with delayed controlled rates of expansion. Methods of forming such devices are also disclosed.

The present invention provides a dry powder that is suitable for use in forming a hydrogel and characterized by a stable composition at ambient conditions. The dry powder includes a prepolymer including a straight chain polyethylene glycol, and a thermally activated free radical initiator selected from the group consisting of sodium persulfate, potassium persulfate, and ammonium persulfate. The present invention also provides a method of forming the dry powder, and a method of preparing a hydrogel where a reaction mixture is formed including the dry powder and a buffered aqueous solution.

The present invention provides a dry powder that is suitable for use in forming a hydrogel and characterized by a stable composition at ambient conditions. The dry powder includes a prepolymer including a straight chain polyethylene glycol, and a thermally activated free radical initiator selected from the group consisting of sodium persulfate, potassium persulfate, and ammonium persulfate. The present invention also provides a method of forming the dry powder, and a method of preparing a hydrogel where a reaction mixture is formed including the dry powder and a buffered aqueous solution.

An echogenic coating composition on a medical device to be inserted into a body at depths greater than 5 cm includes: (i) a polymer matrix and (ii) an amount of ultrasound-reflective microparticles having a diameter that is at least 10 and at most 250 μm in size, with a defined relationship between the particle size, expressed as D50, and the surface density. A method for ultrasound detection of a medical device at a scan depth greater than 5 cm includes: providing the medical device with the echogenic coating composition and to an echogenic assembly including the medical device and a convex probe.

An echogenic coating composition on a medical device to be inserted into a body at depths greater than 5 cm includes: (i) a polymer matrix and (ii) an amount of ultrasound-reflective microparticles having a diameter that is at least 10 and at most 250 μm in size, with a defined relationship between the particle size, expressed as D50, and the surface density. A method for ultrasound detection of a medical device at a scan depth greater than 5 cm includes: providing the medical device with the echogenic coating composition and to an echogenic assembly including the medical device and a convex probe.

A stent having a cobalt-based alloy, wherein the cobalt-based alloy is free of nickel (Ni), the cobalt-based alloy including 10-65 weight % metal member selected from a platinum group metal, a refractory metal, or combinations thereof, 15-25 weight % chromium (Cr), 4-7 weight % molybdenum (Mo), 0-18 weight % iron (Fe), and 22-40 weight % cobalt (Co).

A stent having a cobalt-based alloy, wherein the cobalt-based alloy is free of nickel (Ni), the cobalt-based alloy including 10-65 weight % metal member selected from a platinum group metal, a refractory metal, or combinations thereof, 15-25 weight % chromium (Cr), 4-7 weight % molybdenum (Mo), 0-18 weight % iron (Fe), and 22-40 weight % cobalt (Co).